BMDSX
Price
$16.81
Change
-$0.05 (-0.30%)
Updated
Sep 18 closing price
Net Assets
442.09M
RPTIX
Price
$97.75
Change
-$0.02 (-0.02%)
Updated
Sep 18 closing price
Net Assets
20.82B
Interact to see
Advertisement

BMDSX vs RPTIX

BMDSX vs RPTIX Comparison Chart in %
View a ticker or compare two or three
VS
BMDSX vs. RPTIX commentary
Sep 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMDSX is a Hold and RPTIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 20.8B vs. BMDSX (442M). RPTIX pays higher dividends than BMDSX: RPTIX (0.11) vs BMDSX (0.00). BMDSX was incepted earlier than RPTIX: BMDSX (26 years) vs RPTIX (11 years). BMDSX (1.11) is less costly to investors than RPTIX (0.63). BMDSX is a more actively managed with annual turnover of: 63.00 vs. RPTIX (31.50). BMDSX has a lower initial minimum investment than RPTIX: BMDSX (2500) vs RPTIX (500000). RPTIX annual gain was more profitable for investors over the last year : -5.48 vs. BMDSX (-18.20). RPTIX return over 5 years is better than : -23.75 vs. BMDSX (-46.09).
BMDSXRPTIXBMDSX / RPTIX
Total Expense Ratio1.100.63175%
Annual Report Gross Expense Ratio1.110.63176%
Fund Existence26 years11 years-
Gain YTD-0.5330.164-325%
Front LoadN/AN/A-
Min. Initial Investment25005000001%
Min. Initial Investment IRAN/AN/A-
Net Assets442M20.8B2%
Annual Yield % from dividends0.000.11-
Returns for 1 year-18.20-5.48332%
Returns for 3 years-19.030.28-6,717%
Returns for 5 years-46.09-23.75194%
Returns for 10 years13.4328.9646%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITYRX74.290.53
+0.72%
Invesco Technology R
GGQPX21.700.02
+0.09%
Goldman Sachs Mid Cap Growth P
FGDHX43.410.04
+0.09%
Fidelity Advisor® Dividend Growth I
SEMCX30.46-0.14
-0.46%
SEI Mid-Cap F (SIMT)
BRSSX16.50-0.08
-0.48%
MFS Blended Research Small Cap Eq R2